New episode of NETHERTON NOW features leading UK dermatologist Professor Jemima Mellerio discussing the life-threatening burden of the rare genetic skin disease
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a late clinical-stage biopharmaceutical company targeting rare and orphan diseases has released a new episode in its NETHERTON NOW video series featuring Professor Jemima Mellerio, a globally recognized expert in genetic skin disorders. The video sheds light on the severe impact of Netherton Syndrome, particularly in infants and young children, and the urgent need for safe, effective treatment options.
Professor Mellerio, who serves as Consultant Dermatologist at the St John’s Institute of Dermatology at Guy’s and St Thomas’ NHS Foundation Trust and Honorary Chair of Pediatric Dermatology at King’s College London, emphasized the seriousness of the condition in the video. “Netherton Syndrome is classified as a skin disease called ichthyosis. It’s a genetic condition and we don’t currently have a cure for it,” Mellerio said. “It’s not just the way the skin appears. It’s actually a very serious medical condition and there is associated mortality with it—particularly in young babies and small children.”
She also noted the chronic and demanding nature of managing the disease.
Quoin’s NETHERTON NOW campaign aims to elevate awareness of Netherton Syndrome by featuring insights from clinicians, caregivers, and patients. The addition of Professor Mellerio to the series marks a significant step in highlighting the clinical urgency surrounding this underserved pediatric disease.
“Professor Mellerio brings an important clinical voice to the NETHERTON NOW series,” said Denise Carter, Co-Founder and Chief Operating Officer of Quoin Pharmaceuticals. “Unfortunately, many cases of Netherton Syndrome are still misdiagnosed even though newborns present with very tell-tale signs of compromised skin. The implications for infants can be failure to thrive, severe dehydration, and unexplained severe infections which can, in some cases, be fatal.”
The video release follows Quoin’s recent regulatory milestone: the U.S. Food and Drug Administration granted Rare Pediatric Disease Designation to the company’s lead candidate, QRX003, for the treatment of Netherton Syndrome. Combined with Orphan Drug status from the European Medicines Agency (EMA), the designations underscore the critical need for new therapies for children affected by the condition.
“The experiences shared by Professor Mellerio speak directly to the challenges that children and families face from birth when living with Netherton Syndrome,” said Dr. Michael Myers, Chief Executive Officer of Quoin Pharmaceuticals. “This is a serious pediatric disease with no approved treatments or cures, and we believe QRX003 has the potential to change that. The recent Rare Pediatric Disease Designation from the FDA further reinforces the urgency of our mission.”
The full video interview with Professor Mellerio is now available as part of the ongoing NETHERTON NOW campaign at https://nethertonnow.com.
About Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd. is a late clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa and others. For more information, visit: www.quoinpharma.com or LinkedIn for updates.
This article contains sponsored content. Please see our disclaimer at: https://prismmarketview.com/disclaimer/
The post Quoin Pharmaceuticals Highlights Urgent Pediatric Need in Netherton Syndrome with New Expert Video appeared first on PRISM MarketView.
